TNF and COVID-19: This finding concurs with other studies [29,30] on AIIRD patients that have focused mostly on patients with IBD and which found TNF-α inhibitor monotherapy to be associated with a lower risk of adverse COVID-19-related outcomes when compared with other commonly prescribed immunomodulatory treatment regimens.